Adil Yousaf: Thrombolysis Speed Matters, but Eligibility Comes First
Adil Yousaf, Pharmacy Manager at Green Health Co., shared a post on LinkedIn:
“Thrombolysis is among the most time-critical treatments in medicine but speed never replaces eligibility screening.
Thrombolytics, also called fibrinolytics, accelerate conversion of plasminogen to plasmin, which breaks down fibrin within an existing clot.
They are not interchangeable:
- Alteplase (Activase or Actilyse) is a recombinant tissue plasminogen activator. US labeling includes acute ischemic stroke, acute myocardial infarction and selected acute massive pulmonary embolism.
- Tenecteplase (TNKase or Metalyse) is a modified tPA. Current US and EU authorizations include acute ischemic stroke and STEMI, but labeled time windows and product presentations differ. The 2026 AHA/ASA stroke guideline endorses either alteplase or tenecteplase for eligible patients in the 4.5-hour thrombolytic window.
- Reteplase (Retavase) has a US STEMI indication.
- Urokinase (Kinlytic) has US labeling for selected acute massive pulmonary embolism; current availability must be confirmed locally.
The essential safety pearl is catastrophic bleeding prevention. Before treatment, confirm the diagnosis and review brain imaging when stroke is suspected, blood pressure, bleeding history, recent surgery or trauma, antiplatelet and anticoagulant exposure, and relevant laboratory results.
Which thrombolytic eligibility check is most often delayed or overlooked?
Educational content only not individualized medical advice.”
Stay updated with Hemostasis Today.
-
Oct 23, 2026, 17:45Lucy Brook: Had the Privilege of Attending the Blood 2026 Conference with New Zealand Blood Service
-
Oct 23, 2026, 16:05Platelet Secretion Defects and Their Role in the Diagnosis of Bleeding Disorders
-
Oct 23, 2026, 16:00Hemophilia Alliance team in New Orleans at the ATHN Data Summit
-
Oct 23, 2026, 15:49Brian Sapp: Why Exact Calf Vein Naming Is Critical for DVT Diagnosis?
-
Oct 23, 2026, 15:33Smitirupa Mishra: A Systematic Approach to Bone Marrow Examination
-
Oct 23, 2026, 15:29José Antonio García Erce: Preoperative Anemia Emerges as a Modifiable Surgical Risk in New POWER Study
-
Oct 23, 2026, 15:13Reza Shojaei: Manufactured Red Blood Cells vs Blood Donation
-
Oct 23, 2026, 14:29Jean Jacques Kiladjian: International Scientific Exchange at IHCAMS in Tianjin
-
Oct 23, 2026, 14:11Aravind Palraj: The Prolonged aPTT Puzzle in SLE